Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GV8J
|
|||
| Drug Name |
Talazoparib
|
|||
| Synonyms |
Talazoparib (BMN 673); UNII-9QHX048FRV; 9QHX048FRV; Talazoparib [USAN:INN]; Talzenna; 4pjt; 2YQ
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Approved | [1] | |
| Psoriatic arthritis [ICD-11: FA21; ICD-9: 696] | Phase 3 | [2], [3] | ||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H14F2N6O
|
|||
| Canonical SMILES |
CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
|
|||
| InChI |
1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
|
|||
| InChIKey |
HWGQMRYQVZSGDQ-HZPDHXFCSA-N
|
|||
| CAS Number |
CAS 1207456-01-6
|
|||
| PubChem Compound ID | ||||
| ADReCS Drug ID | BADD_D02485 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Poly [ADP-ribose] polymerase (PARP) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8313). | |||
| REF 3 | ClinicalTrials.gov (NCT01945775) A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.